Compare BioNTech SE - ADR (BNTX) vs Fastly Inc (FSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Fastly Inc — how do they compare? BioNTech SE - ADR trades at $90.19 (market cap $22.86B), while Fastly Inc trades at $20.31 (market cap $3.27B). The key difference: BioNTech SE - ADR is far larger — about 7× Fastly Inc's market cap, and Fastly Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | FSLY | |
|---|---|---|
Market Cap | $22.86B | $3.27B |
Sector | Health | Technology |
52-Week High | $119.34 | $33.50 |
52-Week Low | $83.89 | $6.36 |
Enterprise Value | $6.53B | $3.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Fastly (FSLY) trades at $20.03, up 2.25% today, with a bullish technical signal from moving averages. The company shows improving fundamentals with Q1 2026 EPS beating expectations at $0.13 versus $0.08, and revenue growth accelerating to 20% year-over-year. Recent news highlights strategic partnerships for digital sustainability and edge AI commerce, while cash flow trends indicate potential stabilization with 2026 net cash flow projected positive at $21 million.
Outlook remains cautiously optimistic with a consensus price target of $24.25 offering 21% upside, though persistent net losses and negative ROE pose risks. Investor sentiment is mixed with 29% buy ratings amid competitive pressures in edge cloud services. Key catalysts include Q2 2026 earnings on August 5 and execution on margin expansion targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Read more on FSLY →
